0A64 Stock Overview
A development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Oragenics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.97 |
| 52 Week High | US$7.45 |
| 52 Week Low | US$1.02 |
| Beta | 0.40 |
| 1 Month Change | 86.20% |
| 3 Month Change | -37.56% |
| 1 Year Change | -36.84% |
| 3 Year Change | -95.08% |
| 5 Year Change | n/a |
| Change since IPO | -96.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A64 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 18.0% | 1.0% | -1.2% |
| 1Y | -36.8% | -20.8% | 7.0% |
Return vs Industry: 0A64 underperformed the UK Biotechs industry which returned -20.8% over the past year.
Return vs Market: 0A64 underperformed the UK Market which returned 7% over the past year.
Price Volatility
| 0A64 volatility | |
|---|---|
| 0A64 Average Weekly Movement | 38.8% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.0% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0A64's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0A64's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 5 | Mike Redmond | www.oragenics.com |
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics.
Oragenics, Inc. Fundamentals Summary
| 0A64 fundamental statistics | |
|---|---|
| Market cap | US$9.95m |
| Earnings (TTM) | -US$20.26m |
| Revenue (TTM) | US$20.63k |
482.2x
P/S Ratio-0.5x
P/E RatioIs 0A64 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A64 income statement (TTM) | |
|---|---|
| Revenue | US$20.63k |
| Cost of Revenue | US$15.49m |
| Gross Profit | -US$15.47m |
| Other Expenses | US$4.79m |
| Earnings | -US$20.26m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.52 |
| Gross Margin | -74,991.40% |
| Net Profit Margin | -98,219.66% |
| Debt/Equity Ratio | 4.8% |
How did 0A64 perform over the long term?
See historical performance and comparison